Preterm Infants and Nephrocalcinosis

Overview

Nephrocalcinosis (NC), defined as calcification of renal tissue, has been reported to occur in 7-41% of premature infants. Causes of NC are likely multi-factorial, and infants born prematurely and with very low birth weight (<1500 gm) seem to be at the highest risk of developing NC. Recent changes in recommendations for nutrition for the preterm infant such as higher intakes of protein, calcium, and vitamin D may also play a factor in the pathogenesis of NC. Currently, diagnosis of NC often occurs incidentally during ultrasound evaluation for other issues. Because there is no acute symptom or pattern of symptoms in the preterm population associated specifically with NC, it is possible that many cases of NC may not be diagnosed. Presently, it is impractical and costly to screen all infants for NC with renal ultrasound, therefore there is no standard of care regarding screening for NC. NC may have long-term effects. Studies have shown that preterm infants with NC had shorter kidneys and a lower rate of tubule resorption of phosphorus (TRP) than preterm infants without NC. This study will analyze weekly urinalysis for all enrolled subjects prospectively and then look at the incidence of NC at discharge of the enrolled subjects.

Full Title of Study: “Preterm Infants and Nephrocalcinosis: Diagnosis and Pathogenesis”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: January 2017

Arms, Groups and Cohorts

  • Non-NC group
    • Enrolled subjects who did not have evidence of NC on renal ultrasound
  • NC group
    • Enrolled subjects who did have evidence of NC on renal ultrasound

Clinical Trial Outcome Measures

Primary Measures

  • Urinary calcium to creatinine ratio (UCa/Cr)
    • Time Frame: 3 months
    • Beginning within the first two weeks of life, urine calcium to creatinine ratio (UCa/Cr) will be analyzed weekly through discharge and then correlated to renal ultrasound results done prior to discharge.
  • Urinary crystals
    • Time Frame: 3 months
    • Beginning within the first two weeks of life, urinalysis for evidence of urinary crystallization will be analyzed weekly through discharge and then correlated to renal ultrasound results done prior to discharge.

Secondary Measures

  • Serum Vitamin D levels
    • Time Frame: 3 months
    • Serum vitamin D levels will be analyzed and compared in infants with NC against infants without NC (controls).
  • Vitamin D intake
    • Time Frame: 3 months
    • Daily vitamin D intake will be recorded from participants’ medical records and will be analyzed and compared in infants with NC against infants without NC (controls).
  • Calcium intake
    • Time Frame: 3 months
    • Daily calcium intakes will be recorded from participants’ medical records and will be analyzed and compared in infants with NC against infants without NC (controls).
  • Protein intake
    • Time Frame: 3 months
    • Daily protein intakes will be recorded from participants’ medical records and will be analyzed and compared in infants with NC against infants without NC (controls).
  • Total bone density per DXA
    • Time Frame: 3 months
    • Whole body bone density per dual energy X-ray absorptiometry (DXA) will be done on all enrolled participants at discharge and will be compared between infants with and without NC.
  • Tibial bone density per tibial ultrasound
    • Time Frame: 3 months
    • Tibial body bone density per ultrasound will be done on all enrolled participants at discharge and will be compared between infants with and without NC.

Participating in This Clinical Trial

Inclusion Criteria

  • Infants whose gestation less than or equal to 32 weeks and/or birth weights less than 1800 gm Exclusion Criteria:

  • Infants with congenital abnormalities of the heart, lung, GI, or kidneys that will affect renal function.

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: 2 Weeks

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Utah
  • Collaborator
    • Intermountain Health Care, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Sabrina Malone-Jenkins, MD, Principal Investigator, University of Utah

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.